News
SLP
--
0.00%
--
Global Biosimulation Market Share Survey 2021 with Top Countries Data And Covid-19 Analysis Boosting the Growth Worldwide:Market Key Dynamics,, Trends, Share Valuation Industry Size and Foreseen Research Report
Apr 29, 2021 (The Expresswire) -- Global “Biosimulation Market” research report 2021 analyzed in detail all the vital data to frame tactical business...
The Express Wire · 04/29 05:46
Simulations Plus Releases ADMET Predictor® (X.2)
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer...
BusinessWire - BZX · 04/27 12:30
Biosimulation Market Size to Reach over US$ 7 Billion by 2030
Apr 27, 2021 (Market Stats News via COMTEX) -- The global biosimulation market size surpassed US$ 2.1 Bn in 2020 and expected to reach over US$ 7 billion by...
Market Stats News · 04/27 08:52
Conestoga Capital Advisors, LLC Buys Workiva Inc, Casella Waste Systems Inc, Mercury Systems ...
GuruFocus News · 04/26 09:38
Simulations Plus says DSS, division has renewed licenses to DILIsym
Simulations Plus (SLP) has announced that its DILIsym Services division has renewed licenses to its DILIsym® software platform, for use by the U.S. FDA.The renewal ensures continued DILIsym software access to FDA
Seekingalpha · 04/20 12:52
BRIEF-Simulations Plus- U.S. FDA Renews Licenses Of Dilisym Software
reuters.com · 04/20 12:49
Simulations Plus Says U.S. FDA Renews Licenses of DILIsym Software
U.S. FDA Renews Licenses of DILIsym Software FDA Renewal Allows for Evaluation of DILIsym Submissions by Sponsors Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of modeling and simulation software and services
Benzinga · 04/20 12:37
Simulations Plus Announces FDA Renews Licenses Of Co.'s DILIsym Software
FDA Renewal Allows for Evaluation of DILIsym Submissions by Sponsors Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today
Benzinga · 04/20 12:31
Simulations Plus Secures Software License Renewals from US FDA
MT Newswires · 04/20 10:22
10-Q: SIMULATIONS PLUS, INC.
(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Forward-Looking Statements This...
Edgar Online - (EDG = 10Q, 10K) · 04/14 20:08
Simulations Plus (SLP) Q2 Earnings & Revenues Top Estimates
Simulations Plus' (SLP) fiscal second-quarter results benefit from strong performance of the company's higher-margin software business.
Zacks · 04/14 14:25
Analysts Offer Insights on Technology Companies: Simulations Plus (SLP) and Atlassian (TEAM)
Analysts have been eager to weigh in on the Technology sector with new ratings on Simulations Plus (SLP) and Atlassian (TEAM). Simulations Plus (SLP)
SmarterAnalyst · 04/14 11:15
DJ Slack, Fastenal, FedEx: What to Watch When the Stock Market Opens Today
Dow Jones · 04/13 11:02
DJ Simulations Plus, Inc.'s CEO Shawn O'Connor on Q2 2021 Results -- Earnings Call Transcript >SLP
Dow Jones · 04/13 00:43
Simulations Plus (SLP) Q2 Earnings and Revenues Surpass Estimates
Simulations Plus (SLP) delivered earnings and revenue surprises of 7.14% and 1.68%, respectively, for the quarter ended February 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 04/12 22:15
BRIEF-Simulations Plus Q2 Earnings Per Share $0.15
reuters.com · 04/12 20:11
Simulations Plus declares $0.06 dividend
Simulations Plus (SLP) declares $0.06/share quarterly dividend, in line with previous.Forward yield 0.38%Payable May 3; for shareholders of record April 26; ex-div April 23.See SLP Dividend Scorecard, Yield Chart, &
Seekingalpha · 04/12 20:10
Simulations Plus Q2 EPS $0.15 Beats $0.14 Estimate, Sales $13.10M Beat $12.84M Estimate
Simulations Plus (NASDAQ:SLP) reported quarterly earnings of $0.15 per share which beat the analyst consensus estimate of $0.14 by 7.14 percent. This is a 25 percent increase over earnings of $0.12 per share from the
Benzinga · 04/12 20:08
Simulations Plus EPS beats by $0.01, beats on revenue
Simulations Plus (SLP): FQ2 GAAP EPS of $0.15 beats by $0.01.Revenue of $13.15M (+27.1% Y/Y) beats by $0.31M.Gross margin was 78%, up from 74%.“While we expect growth to normalize in
Seekingalpha · 04/12 20:07
Simulations Plus 2Q EPS 15c >SLP
Simulations Plus 2Q EPS 15c >SLP
Dow Jones · 04/12 20:07
Webull provides a variety of real-time SLP stock news. You can receive the latest news about Simulations Plus through multiple platforms. This information may help you make smarter investment decisions.
About SLP
Simulations Plus, Inc. is a developer of drug discovery and development software for mechanistic modeling and simulation, for machine-learning-based prediction of properties of molecules from their structure, and is exploring the application of its machine-learning technologies in other industries, including aerospace/military and general healthcare. The Company offers its products and services through two business segments, which include Simulations Plus, Inc. and Cognigen Corporation. Cognigen Corporation is the subsidiary of the Company. Its pharmaceutical/chemistry software is used by various companies, such as pharmaceutical, biotechnology, agrochemical, and food industry companies and to regulatory agencies for use in the conduct of industry-based research. Its clinical-pharmacology-based consulting services include pharmacokinetic and pharmacodynamics modeling, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions.